What is the current market valuation of the glioma diagnosis-treatment market in China as of 2024?

The market valuation was $268.27 Million in 2024. Read More

What is the projected market valuation for the glioma diagnosis-treatment market in China by 2035?

The projected valuation for 2035 is $509.46 Million. Read More

What is the expected CAGR for the glioma diagnosis-treatment market in China during the forecast period 2025 - 2035?

The expected CAGR during this period is 6.0%. Read More

Which companies are the key players in the glioma diagnosis-treatment market in China?

Key players include Roche, Novartis, Merck, Bristol-Myers Squibb, Eli Lilly, Amgen, AstraZeneca, Pfizer, and Bayer. Read More

What are the primary types of gliomas and their market valuations in China?

Primary tumors are valued between $160.0 Million and $300.0 Million, while secondary tumors range from $108.27 Million to $209.46 Million. Read More

What diagnostic methods are utilized in the glioma diagnosis-treatment market in China?

Diagnostic methods include MRI valued at $60.0 Million to $100.0 Million and CT scans valued at $40.0 Million to $70.0 Million. Read More

What are the treatment options available for glioma patients in China?

Treatment options include chemotherapy valued at $70.0 Million to $130.0 Million and radiation therapy valued at $60.0 Million to $120.0 Million. Read More

How are gliomas categorized by grade in the Chinese market?

Gliomas are categorized by grade, with low grade gliomas valued at $40.0 Million to $80.0 Million and high grade gliomas at $150.0 Million to $300.0 Million. Read More

What are the end-user segments in the glioma diagnosis-treatment market in China?

End-user segments include hospitals and clinics valued at $100.0 Million to $190.0 Million and diagnostic centers valued at $70.0 Million to $130.0 Million. Read More

What locations are primarily affected by gliomas in China?

Gliomas are primarily located in supratentorial regions valued at $160.0 Million to $300.0 Million and infratentorial regions valued at $108.27 Million to $209.46 Million. Read More

China Glioma Diagnosis Treatment Market

ID: MRFR/HC/52774-HCR

200 Pages

Vikita Thakur

Last Updated: February 06, 2026

China Glioma Diagnosis and Treatment Market Research Report: Size, Share, Trend Analysis By Types (Primary Tumors, Secondary Tumors), By Diagnosis (Neurological Exam, CT Scan, MRI, PET Scan, Biopsy, Molecular Testing, EEG, Others), By Treatment (Surgery, Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy), By Grade (Low Grade Glioma, High Grade Glioma, Recurrent High Grade Glioma), By Location (Supratentorial, Infratentorial) and By End Users (Hospitals and amp; Clinics, Diagnostic Centers, Medical Research Centers, Others)- Growth Outlook & Industry Forecast 2025 To 2035

China Glioma Diagnosis Treatment Market Infographic

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Security, Access Control and Robotics, BY Type (USD Million)
  1. 4.1.1 Primary Tumors
  2. 4.1.2 Secondary Tumors
2. 4.2 Security, Access Control and Robotics, BY Diagnosis (USD Million)
  1. 4.2.1 Neurological Exam
  2. 4.2.2 CT Scan
  3. 4.2.3 MRI
  4. 4.2.4 PET Scan
  5. 4.2.5 Biopsy
  6. 4.2.6 Molecular Testing
  7. 4.2.7 EEG
  8. 4.2.8 Others
3. 4.3 Security, Access Control and Robotics, BY Treatment (USD Million)
  1. 4.3.1 Surgery
  2. 4.3.2 Chemotherapy
  3. 4.3.3 Radiation Therapy
  4. 4.3.4 Immunotherapy
  5. 4.3.5 Targeted Therapy
4. 4.4 Security, Access Control and Robotics, BY Grade (USD Million)
  1. 4.4.1 Low Grade Glioma
  2. 4.4.2 High Grade Glioma
  3. 4.4.3 Recurrent High Grade Glioma
5. 4.5 Security, Access Control and Robotics, BY Location (USD Million)
  1. 4.5.1 Supratentorial
  2. 4.5.2 Infratentorial
6. 4.6 Security, Access Control and Robotics, BY End User (USD Million)
  1. 4.6.1 Hospitals & Clinics
  2. 4.6.2 Diagnostic Centers
  3. 4.6.3 Medical Research Centers
  4. 4.6.4 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Security, Access Control and Robotics
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Security, Access Control and Robotics
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Roche (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Novartis (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Merck (DE)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Bristol-Myers Squibb (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Eli Lilly (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Amgen (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 AstraZeneca (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Pfizer (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Bayer (DE)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 CHINA MARKET ANALYSIS BY TYPE
3. 6.3 CHINA MARKET ANALYSIS BY DIAGNOSIS
4. 6.4 CHINA MARKET ANALYSIS BY TREATMENT
5. 6.5 CHINA MARKET ANALYSIS BY GRADE
6. 6.6 CHINA MARKET ANALYSIS BY LOCATION
7. 6.7 CHINA MARKET ANALYSIS BY END USER
8. 6.8 KEY BUYING CRITERIA OF SECURITY, ACCESS CONTROL AND ROBOTICS
9. 6.9 RESEARCH PROCESS OF MRFR
10. 6.10 DRO ANALYSIS OF SECURITY, ACCESS CONTROL AND ROBOTICS
11. 6.11 DRIVERS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
12. 6.12 RESTRAINTS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
13. 6.13 SUPPLY / VALUE CHAIN: SECURITY, ACCESS CONTROL AND ROBOTICS
14. 6.14 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TYPE, 2024 (% SHARE)
15. 6.15 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TYPE, 2024 TO 2035 (USD Million)
16. 6.16 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DIAGNOSIS, 2024 (% SHARE)
17. 6.17 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
18. 6.18 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TREATMENT, 2024 (% SHARE)
19. 6.19 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TREATMENT, 2024 TO 2035 (USD Million)
20. 6.20 SECURITY, ACCESS CONTROL AND ROBOTICS, BY GRADE, 2024 (% SHARE)
21. 6.21 SECURITY, ACCESS CONTROL AND ROBOTICS, BY GRADE, 2024 TO 2035 (USD Million)
22. 6.22 SECURITY, ACCESS CONTROL AND ROBOTICS, BY LOCATION, 2024 (% SHARE)
23. 6.23 SECURITY, ACCESS CONTROL AND ROBOTICS, BY LOCATION, 2024 TO 2035 (USD Million)
24. 6.24 SECURITY, ACCESS CONTROL AND ROBOTICS, BY END USER, 2024 (% SHARE)
25. 6.25 SECURITY, ACCESS CONTROL AND ROBOTICS, BY END USER, 2024 TO 2035 (USD Million)
26. 6.26 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY DIAGNOSIS, 2025-2035 (USD Million)
  3. 7.2.3 BY TREATMENT, 2025-2035 (USD Million)
  4. 7.2.4 BY GRADE, 2025-2035 (USD Million)
  5. 7.2.5 BY LOCATION, 2025-2035 (USD Million)
  6. 7.2.6 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

China Security, Access Control and Robotics Market Segmentation

Security, Access Control and Robotics By Type (USD Million, 2025-2035)

Primary Tumors
Secondary Tumors

Security, Access Control and Robotics By Diagnosis (USD Million, 2025-2035)

Neurological Exam
CT Scan
MRI
PET Scan
Biopsy
Molecular Testing
EEG
Others

Security, Access Control and Robotics By Treatment (USD Million, 2025-2035)

Surgery
Chemotherapy
Radiation Therapy
Immunotherapy
Targeted Therapy

Security, Access Control and Robotics By Grade (USD Million, 2025-2035)

Low Grade Glioma
High Grade Glioma
Recurrent High Grade Glioma

Security, Access Control and Robotics By Location (USD Million, 2025-2035)

Supratentorial
Infratentorial

Security, Access Control and Robotics By End User (USD Million, 2025-2035)

Hospitals & Clinics
Diagnostic Centers
Medical Research Centers
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓